Agreed. Without non dilutive funding from big pharma, it becomes clear that endless dilution will continue for many years. Likely over 3B shares in 2028 and trading in single digit cents.
Gary will be pumping a .20 cent share price by end of 2028, which will give shareholders a whopping 3 to 4 X return in a few months!
Doc Logic will be saying manufacturing, manufacturing, manufacturing, while LP informs shareholders that they have narrowed down on another version of Flaskworks for testing in 2028. However, LP points to supply chain issue with some parts. Doc Logic claims they will finally hit $90M in annual revenue in 2029.
ATL and Zivic will be pumping worldwide reimbursement approvals while NICE reimbursement approval in UK hasn’t come through yet! ;)
Market Data 
Markets 
AI
